Moderna Inc at Goldman Sachs Healthcare Conference Transcript
Great. Good afternoon, everyone. Thanks so much for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. Really pleased to have the team from Moderna here today. So we have Jamie Mock, CFO; and Lavina Talukdar, Head of IR.
Questions & Answers
So with that, maybe we'll start here with some financial questions. You provided some guidance in the beginning of the year and -- on COGS and other aspects. Could you just help us understand what COGS is going to look like for this year and beyond? And what the key components are on this line and how they change over time as commercialize COVID, as that market is better understood and then additional assets are commercialized?
Terrific. Yes. Well, first, thanks for having us, Salveen. Pleasure to be here. And thanks, everybody, for joining. Yes. So as we transition
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |